The presentation of positive data from two studies at a significant medical congress tends to have a favorable impact on the stock of the presenting company. For Aurinia Pharmaceuticals, showcasing the safety and effectiveness of LUPKYNIS in treating lupus nephritis, a serious condition, could enhance its market position and investor sentiment, leading to a potential short-term uptick in its stock price.